Year Founded
2017
Ownership
Public
Employees
~310
Stage
Commercial
Modalities
Small molecule

Urovant Sciences General Information

Lead product GEMTESA (vibegron) received FDA approval for overactive bladder. Demonstrated significant reduction in OAB symptoms vs placebo at Week 12 in Phase 3 EMPOWUR study with favorable long-term safety in 40-week extension.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Irvine, California
United States

Drug Pipeline

vibegron
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Urovant Sciences's pipeline data

Book a demo

Key Partnerships

Sumitomo Dainippon Pharma, Sunovion, Merck Sharp & Dohme Corp, Ion Channel Innovations

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Urovant Sciences Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Urovant Sciences's complete valuation and funding history, request access »